26 recruiting, 7 not yet recruiting, 6 completed, 5 active not recruiting. 22 Phase 2, 11 Phase 1, 5 Phase 3, 2 Phase 4, 1 Not applicable.
Follow Elranatamab: new trials by email Literature Review of Elranatamab trials Research Report on Elranatamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma Elranatamab, Standard of Care - Multiple Myeloma | Not yet recruiting | Pfizer | 1 | 2026-11-09 | 2026-11-09 | |
| Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Dexamethasone, Mezigdomide, Elranatamab - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | PETHEMA Foundation | 60 | 2026-11-01 | 2026-10-28 |
| A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments Elranatamab - Relapsed/Refractory Multiple Myeloma, Multiple Myeloma | Phase 4 | Not yet recruiting | Pfizer | 75 | 2026-10-22 | 2026-10-19 |
| A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A Elranatamab - Hemophilia A With Inhibitors | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-10-01 | 2026-08-26 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 46 | 2026-09-01 | 2026-09-04 |
| Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis BCMA bispecific - Amyloid Light-chain Amyloidosis | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 64 | 2026-08-01 | 2026-08-05 |
| A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" Elranatamab - Phase 2, Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 34 | 2026-03-31 | 2026-09-18 |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects Cemsidomide, Elranatamab - Multiple Myeloma (MM) | Phase 1 | Recruiting | C4 Therapeutics, Inc. | 60 | 2026-02-06 | 2026-10-30 |
| ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab Elranatamab - TCE-RRMM | Not yet recruiting | Peking University People's Hospital | 159 | 2025-12-30 | 2026-01-06 | |
| A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Celgene | 62 | 2025-10-07 | 2026-09-02 |
| ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0) Lenalidomide, Dexamethasone, Elranatamab - Multiple Myeloma | Phase 2 | Recruiting | University of Miami | 104 | 2025-09-16 | 2026-09-21 |
| Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy Letermovir - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 2 | Recruiting | Seoul National University Hospital | 40 | 2025-09-11 | 2025-12-03 |
| ELISA in Relapsed/Refractory MM elranatamab, Isatuximab SC, Isatuximab SC-OBDS - Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2025-08-14 | 2026-09-16 |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM) | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 100 | 2025-08-08 | 2026-06-04 |
| Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients Elranatamab, Lenalidomide (Revlimid®), Daratumumab SC (Darzalex) - Multiple Myeloma, Newly Diagnosed | Phase 3 | Recruiting | Intergroupe Francophone du Myelome | 824 | 2025-07-09 | 2026-09-30 |
| Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). Elranatamab - Multiple Myeloma | Active not recruiting | Pfizer | 150 | 2025-06-05 | 2026-10-29 | |
| Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma Elranatamab - Myeloma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 39 | 2025-05-27 | 2025-12-03 |
| Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 2 | Not yet recruiting | Nantes University Hospital | 176 | 2025-05-01 | 2025-04-23 |
| A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma Elranatamab, GM-CSF, DC/MM Fusion Vaccine - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2025-01-31 | 2026-05-07 |
| Self-administration of Subcutaneous Elranatamab in the Patients' Homes. Elranatamab - Multiple Myeloma | Phase 2 | Recruiting | Thomas Lund | 20 | 2025-01-29 | 2026-02-10 |
Showing 20 of 45. Sign in to see all of them.
Multiple Myeloma (39) · Neoplasms, Plasma Cell (8) · Recurrence (8) · Immunoglobulin Light-chain Amyloidosis (3) · Hematologic Diseases (2) · Bites and Stings (1) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Neoplasms (1) · Hemophilia A (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Infections (1)
Pfizer (17) · M.D. Anderson Cancer Center (2) · Massachusetts General Hospital (2) · SCRI Development Innovations, LLC (2) · AstraZeneca (1) · C4 Therapeutics, Inc. (1) · Case Comprehensive Cancer Center (1) · Celgene (1) · CellCentric Ltd. (1) · Dana-Farber Cancer Institute (1) · David Avigan (1) · European Myeloma Network B.V. (1) · Genentech, Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
United States (29) · Canada (9) · China (9) · France (9) · Spain (9) · Australia (8) · South Korea (8) · United Kingdom (8) · Germany (7) · Japan (7) · Norway (6) · Taiwan (6) · Belgium (5) · Brazil (5) · Greece (5)
Noopur Raje, MD (2) · Ah-Reum Jeong (1) · Albert Oriol, PhD (1) · Carl O Landgren, MD (1) · Christine Ye, MD (1) · David Avigan, MD (1) · Enrique Ocio, PhD (1) · Giada Bianchi (1) · Hans Lee, MD (1)
PMID 17574838, PMID 27511158, PMID 30858549, PMID 33796236, PMID 34303157, PMID 35332278, PMID 36826140, PMID 37471687, PMID 37582952, PMID 38415370, PMID 38717869, PMID 38937492, PMID 39001399, PMID 39055646, PMID 39755360, PMID 40000533, PMID 40826257, PMID 42287565, PMID 8433390, PMID 9161109
2023 (6), 2025 (1)